Today: 20 May 2026
AI stocks jump as Meta’s Corning deal hits “plumbing” plays; CoreWeave extends Nvidia bump
27 January 2026
2 mins read

AI stocks jump as Meta’s Corning deal hits “plumbing” plays; CoreWeave extends Nvidia bump

New York, Jan 27, 2026, 10:25 EST — Regular session

  • Corning surged 12.9%, while CoreWeave climbed 8.5% amid a rush into AI data-center supply chain stocks.
  • Micron jumped 4.8%, with Nvidia, AMD, and Broadcom gaining roughly 1% to 2% in early trading.
  • Meta dipped 0.7% ahead of its earnings report scheduled for Wednesday.

Corning shares surged to $107.18, with CoreWeave gaining ground at $106.65 on Tuesday, leading a group of AI-related stocks that have been acting as a proxy for data-center expansion bets. Nvidia ticked up 1.0%, while AMD and Broadcom each advanced roughly 1.5%; Micron outpaced them all. Meta shares slipped.

The market is focused on distinguishing “AI demand” from “AI bills” at this moment. Traders are zeroing in on where the spending hits — cables, chips, memory, and the equipment used to produce them — as a packed earnings week sheds new light on spending strategies.

Meta announced plans to pay Corning as much as $6 billion over the coming years to provide fiber-optic cables and connectivity equipment for its AI data centers. Corning will boost its production capacity in North Carolina. CEO Wendell Weeks described the move as an effort to “strengthen domestic supply chains,” according to statements released alongside the deal. Reuters

CoreWeave’s shares jumped after Nvidia revealed a $2 billion stake on Monday, making the chip giant the AI cloud provider’s second-largest backer, according to Reuters. The company, part of the so-called “neoclouds” that lease high-end AI chips, said the funding will support securing land and power as it aims for over 5 gigawatts of data-center capacity by 2030. CEO Michael Intrator described the move as proof of “the strength of demand” CoreWeave is experiencing. Reuters

Micron announced plans to invest $24 billion in a chip manufacturing facility in Singapore over the next ten years, targeting a relief in memory shortages driven by AI demand. The company expects wafer production to kick off in the latter half of 2028. Alongside this, Micron is constructing a $7 billion high-bandwidth memory (HBM) packaging plant in Singapore, slated to begin output in 2027. HBM is a memory type stacked close to AI processors to enhance data transfer speeds. TrendForce analyst Bryan Ao warned that enterprise solid-state drive contract prices could surge 55% to 60%, as demand continues to outpace supply.

In Europe, investors are zeroing in on ASML, the Dutch company that leads in extreme ultraviolet (EUV) lithography — the chip “printer” essential for cutting-edge semiconductors. Analysts told Reuters that all eyes will be on Wednesday’s earnings report to see if ASML raises its 2026 guidance. John West of the consultancy Yole Group described EUV as “the only game in town.” Reuters

Big Tech earnings hit the spotlight this week, with Microsoft and Meta set to report on Wednesday. Investors want proof that their hefty spending is driving real growth. Reuters noted that Microsoft, Meta, and Amazon plan to boost their AI budgets by 30%, pushing total investment past $500 billion this year. David Wagner, head of equities at Aptus Capital Advisors, warned that “proprietary ecosystems” remain tough to penetrate as the focus shifts from flashy demos to actual distribution and cash flow. Reuters

That said, the trade has its vulnerabilities: budgets often climb faster than revenue, and physical limits are tangible. Power, networking equipment, and memory may all create bottlenecks, with any slip in guidance likely to hit the high-multiple stocks hardest.

Wednesday brings a triple whammy: Meta and Microsoft report in the U.S., while ASML delivers its update from Europe. Investors will zero in on capex plans and fresh clues about capacity — who’s ready to ship, and on what timeline.

Stock Market Today

  • FS KKR Capital Corp Offers 15.3% Yield Amid Dividend Cuts and $600M Management Buy-In
    May 20, 2026, 10:08 AM EDT. FS KKR Capital Corp (FSK) presents a compelling 15.3% yield despite recent two consecutive dividend cuts, drawing investor interest due to management's strategic response. The firm, a business development company (BDC) managed by KKR, is facing credit challenges from struggling middle-market borrowers amid rising interest rates, with non-accrual loans increasing to 4.2%. FSK shares trade at 58 cents on the dollar, significantly below book value, reflecting market pessimism. In response, KKR is investing $600 million to support the stock, including purchasing $150 million in preferred shares convertible at net asset value (NAV). This capital infusion aims to shrink the valuation discount and boost share buybacks, indicating potential price appreciation as credit conditions stabilize.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
USBC stock jumps in premarket after Uphold, Vast Bank tokenized-deposit deal
Previous Story

USBC stock jumps in premarket after Uphold, Vast Bank tokenized-deposit deal

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Next Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Go toTop